- Home
- DTCK vs BCAB Comparison
DTCK vs BCAB Comparison
Compare DTCK & BCAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTCK
- BCAB
- Stock Information
- Founded
- DTCK 1999
- BCAB 2007
- Country
- DTCK Singapore
- BCAB United States
- Employees
- DTCK N/A
- BCAB N/A
- Industry
- DTCK Farming/Seeds/Milling
- BCAB Medicinal Chemicals and Botanical Products
- Sector
- DTCK Industrials
- BCAB Health Care
- Exchange
- DTCK Nasdaq
- BCAB Nasdaq
- Market Cap
- DTCK 25.7M
- BCAB 27.0M
- IPO Year
- DTCK 2023
- BCAB 2020
- Fundamental
- Price
- DTCK $0.69
- BCAB $0.28
- Analyst Decision
- DTCK
- BCAB Buy
- Analyst Count
- DTCK 0
- BCAB 2
- Target Price
- DTCK N/A
- BCAB $1.00
- AVG Volume (30 Days)
- DTCK 31.9K
- BCAB 582.8K
- Earning Date
- DTCK 11-13-2024
- BCAB 05-13-2025
- Dividend Yield
- DTCK N/A
- BCAB N/A
- EPS Growth
- DTCK N/A
- BCAB N/A
- EPS
- DTCK 0.02
- BCAB N/A
- Revenue
- DTCK $159,836,000.00
- BCAB $11,000,000.00
- Revenue This Year
- DTCK N/A
- BCAB N/A
- Revenue Next Year
- DTCK N/A
- BCAB N/A
- P/E Ratio
- DTCK $39.69
- BCAB N/A
- Revenue Growth
- DTCK N/A
- BCAB N/A
- 52 Week Low
- DTCK $0.75
- BCAB $0.24
- 52 Week High
- DTCK $1.73
- BCAB $4.02
- Technical
- Relative Strength Index (RSI)
- DTCK 31.17
- BCAB 32.90
- Support Level
- DTCK $0.75
- BCAB $0.28
- Resistance Level
- DTCK $1.10
- BCAB $0.36
- Average True Range (ATR)
- DTCK 0.05
- BCAB 0.04
- MACD
- DTCK -0.02
- BCAB -0.00
- Stochastic Oscillator
- DTCK 4.90
- BCAB 1.79
About DTCK Davis Commodities Limited
Davis Commodities Ltd is an agricultural commodity trading company based in Singapore which specializes in trading of three main categories of agricultural commodities namely sugar, rice, and oil and fat products. It distributes agricultural commodities to various markets, including Asia, Africa and the Middle East. The company also provides customers of commodity offerings with complementary, ancillary services such as warehouse handling and storage and logistics services. The Company operates across four main segments: the sale of sugar, rice, oil and fat products, and others. Among these, the sale of sugar stands out as the primary revenue generator, contributing significantly to the company's overall income.
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.